Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak

(Reuters) - Drugmaker Mylan NV's merger with Pfizer Inc's off-patent branded drug unit, Upjohn, will now close in the second half of this year, the companies said on Thursday, blaming the coronavirus pandemic for the delay.Due to restrictions on large gatherings, the general meeting of shareholders to approve certain matters for the deal to go through has been postponed to June 30, Mylan said. There were no other changes to previously announced terms or plans pertaining to the deal, previously..